Business
GSK Doubles Down on Cancer With a $750M Bet on a Triple-Targeting Immune Drug
GSK is paying up to $750 million for global rights to Chimagen’s trispecific T-cell engager for multiple myeloma — the latest sign of the company rebuilding the oncology franchise it sold off a decade ago.